Clinical trials: Unresectable Locally Advanced Cancer
Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
This phase II trial tests whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alone in treating patients with liver cancer that cannot be removed by…
- Conditions
- Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT05168163
- Testing
- Atezolizumab, Cabozantinib, Lenvatinib
- Where
- 16 sites in United States
- Volunteers
- 122 people
- Sponsor
- Academic and Community Cancer Research United
Locally Advanced Thymoma
Neoadjuvant Radiotherapy for Locally Advanced Unresectable Thymoma
The goal of this prospective, randomized, controlled phase II clinical study is to evaluate the efficacy and safety of neoadjuvant radiotherapy in patients with locally advanced unresectable thymoma.
- Trial name
- NCT06924619
- Testing
- neoadjuvant radiotherapy, cisplatin
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Solid Tumor (Phase I)
This Clinical Study is to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Antitumor Activity of BD200 in Participants With Advanced or Metastatic Cancer.
The Phase 1 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of BD200 in adult participants with advanced solid cancers.
- Trial name
- NCT07797907
- Testing
- BD200
- Volunteers
- 110 people
- Sponsor
- Biolojic Design Ltd.
Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other…
- Conditions
- Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm
- Trial name
- NCT04665739
- Testing
- Biospecimen Collection, Computed Tomography, Everolimus
- Where
- 29 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Neoplasm
Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer
In patients with esophageal cancer, treatment with curative intent can be given to medically fit patients without distant metastases. It may consist of chemoradiotherapy or surgery alone or in combination.
- Trial name
- LERFOX-C (NCT02636088)
- Testing
- Cetuximab
- Volunteers
- 51 people
- Sponsor
- Gabriella Alexandersson von Döbeln
Adenocarcinoma of the Pancreas, Locally Advanced
Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas
This study is a phase 2, multicenter, randomized, double-blind, active placebo-controlled trial of AMG 479 or placebo in combination with gemcitabine as first-line therapy for locally advanced unresectable adenocarinoma of the…
- Conditions
- Adenocarcinoma of the Pancreas, Locally Advanced, Unresectable
- Trial name
- NCT01318642
- Testing
- Gemcitabine, AMG 479
- Where
- 35 sites in United States, Austria and 11 more
- Volunteers
- 10 people
- Sponsor
- NantBioScience, Inc.
Metastatic Urothelial Cancer
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).
- Trial name
- TROPHY U-01 (NCT03547973)
- Testing
- Sacituzumab Govitecan-hziy, Pembrolizumab, Cisplatin
- Where
- 128 sites in United States, France and 7 more
- Volunteers
- 502 people
- Sponsor
- Gilead Sciences
Gastric Cancer
Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer
This study aims to evaluate the efficacy of disitamab vedotin in combination with sintilimab and SOX as conversion therapy in patients with initially unresectable locally advanced or metastatic gastric cancer exhibiting HER2 IHC…
- Trial name
- Remission (NCT07194005)
- Testing
- Disitamab vedotin(RC48), Sintilimab, S-1
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in…
- Trial name
- PACIFIC-8 (NCT05211895)
- Testing
- Durvalumab, Domvanalimab
- Where
- 226 sites in United States, Belgium and 26 more
- Volunteers
- 791 people
- Sponsor
- AstraZeneca
Solid Tumors, Neoplasms (Cancer / Tumors)
Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor
The goal of this clinical trial is to learn if Trastuzumab Rezetecan can treat advanced solid tumors with HER-2 expression in adult participants.
- Conditions
- Solid Tumors, Neoplasms (Cancer / Tumors), Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid Neoplasm
- Trial name
- NCT07631884
- Testing
- Trastuzumab Rezetecan
- Volunteers
- 15 people
- Sponsor
- Haihua Yuan
Lung Cancer, Non-squamous, Non-small Cell
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including…
- Trial name
- NCT06151574
- Testing
- zongertinib, pembrolizumab, cisplatin
- Where
- 163 sites in United States, Argentina and 24 more
- Volunteers
- 428 people
- Sponsor
- Boehringer Ingelheim
Lung Cancer
Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC
Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy and subsequent concomitantly with radiotherapy (RT) in patients with lung cancer (NSCLC) locally advanced unresectable
- Trial name
- NORA (NCT02709720)
- Testing
- Vinorelbine, Cisplatin, Radiotherapy
- Where
- 18 sites in Spain
- Volunteers
- 68 people
- Sponsor
- Spanish Lung Cancer Group
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
This study is for people in South Korea who have cancer in or around the stomach (gastric cancer) or cancer where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer.
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT06902545
- Testing
- zolbetuximab
- Where
- 15 sites in South Korea
- Volunteers
- 377 people
- Sponsor
- Astellas Pharma Korea, Inc.
Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma
Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery
This phase II trial studies the side effects and how well sunitinib malate works in treating patients with cervical cancer which cannot be cured by standard therapy.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Cancer
- Trial name
- NCT00389974
- Testing
- sunitinib malate
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Unresectable Pancreatic Cancer
Chemotherapy Followed by Irreversible Electroporation in Patients With Unresectable Locally Advanced Pancreatic Cancer
This study is a single-arm clinical trial of irreversible electroporation (IRE) for the treatment of unresectable locally advanced pancreatic cancer (LAPC).
- Trial name
- CHEMOFIRE-2 (NCT04093141)
- Testing
- IRE
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery
Non Small Cell Lung Cancer (Stage III)
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer
- Trial name
- LAURA (NCT03521154)
- Testing
- Osimertinib 80mg/40mg
- Where
- 118 sites in United States, Argentina and 15 more
- Volunteers
- 216 people
- Sponsor
- AstraZeneca
Unresectable, Locally Advanced
Cetuximab + Gemox in Biliary Tract Cancer
The aim of this prospective single-centre phase II study is to investigate the therapeutic efficacy and safety of cetuximab in combination with Gemcitabine and Oxaliplatin (GEMOX) in the palliative first line treatment of biliary…
- Conditions
- Unresectable, Locally Advanced, Metastatic
- Trial name
- NCT01216345
- Testing
- Cetuximab + Gemcitabine + Oxaliplatin
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Association of Research on the Biology of Liver Tumors
Stage III Non-small Cell Lung Cancer, Locally Advanced
PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC
Multinational, randomized, controlled, open-label, multicenter phase II trial. Eligible patients will be randomized in a ratio of 1:1 to Experimental Arm (FDG-PET-based small volume accelerated radiotherapy with concurrent…
- Conditions
- Stage III Non-small Cell Lung Cancer, Locally Advanced, Unresectable
- Trial name
- PACCELIO (NCT06102057)
- Testing
- standard Radiotherapy, Chemotherapy, Immunotherapy
- Where
- 11 sites in Germany, Switzerland
- Volunteers
- 110 people
- Sponsor
- TheraOp
Squamous Cell Carcinoma, Head and Neck Cancer
Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma
Whether low-dose radiation in addition to Taxotere and Erbitux improves the response rate of patients with recurrent unresectable head and neck squamous cell carcinoma.
- Conditions
- Squamous Cell Carcinoma, Head and Neck Cancer, Recurrent Disease
- Trial name
- NCT01794845
- Testing
- Erbitux, Taxotere, Low Dose Fractionated Radiation Therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Miami
Pancreatic Ductal Adenocarcinoma
EUS-RFA for Unresectable Pancreatic Cancer
The clinical application of intraoperative or percutaneous radiofrequency ablation (RFA) for pancreatic ductal adenocarcinoma (PDAC) is limited due to higher mortality and incidence of adverse events.
- Trial name
- NCT04310111
- Testing
- EUS-RFA
- Where
- China
- Volunteers
- 8 people
- Sponsor
- First People's Hospital of Hangzhou
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.